Syndax is ending development of Niktimvo for idiopathic pulmonary fibrosis after a Phase 2 failure, the report says. The placebo-controlled study did not deliver the hoped-for clinical benefit, closing out the company’s rare-lung disease ambitions for the asset and forcing a portfolio reset.